Clinical trial NCT04493619: PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
Official title: A Multicenter, Open-Label, Parallel, Phase 2a Study of PLX2853 Monotherapy in Advanced Gynecological Malignancies With a Known ARID1A Mutation and Phase 1b/2a Study of PLX2853/Carboplatin Combination Therapy in Platinum-Resistant Epithelial Ovarian Cancer
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Gynecologic Neoplasms
Epithelial Ovarian Cancer
Keywords: PLX2853
Ovarian Cancer
ARID1A
Gynecological Malignancies
Carboplatin
Lead sponsor: Opna Bio LLC
Sponsor class: INDUSTRY
First posted: 2020-07-30
Enrollment: 37
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in Advanced Gynecological Malignancies with a Known ARID1A Mutation and PLX2853/Carboplatin Combination Therapy in Platinum-Resistant Epithelial Ovarian Cancer.


Eligibility criteria: Inclusion Criteria:

1. Age ≥18 years at the time of signing informed consent
2. Histologically or cytologically confirmed diagnosis of 1 of the following, and must have measurable disease per RECIST v1.1:

   * Phase 2a (PLX2853 monotherapy): Any advanced gynecological malignancy (cervical, vaginal, vulvar, uterine, ovarian, fallopian tube, or primary peritoneal) with a known ARID1A mutation, that is intolerant to or refractory to all standard therapy known to confer clinical benefit.
   * Phase 1b and Phase 2a (PLX2853 + carboplatin combination):

   Platinum-resistant EOC (including fallopian tube or primary peritoneal cancer).
3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1
4. Adequate organ function as demonstrated by laboratory values.
5. Women of child bearing potential (defined as any female who has experienced menarche and who has not undergone successful surgical sterilization or is not postmenopausal) must have a negative serum pregnancy test within 7 days prior to taking the first dose of study drug and, if sexually active, must agree to use a highly effective method of contraception (a contraception method with a failure rate \<1% per year) and 1 additional barrier method from the time of the negative pregnancy test to 90 days after the last dose of study drug. Women of non-child bearing potential may be included if they are either surgically sterile or have been postmenopausal for ≥1 year.
6. Except as specified above for organ function, all drug-related toxicity from previous cancer therapy must be resolved (to Grade ≤1 or baseline per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 \[NCI CTCAE v5.0\]) prior to study treatment administration (Grade 2: alopecia, hot flashes, decreased libido, or neuropathy is allowed).
7. Willingness and ability to provide written informed consent prior to any study-related procedures and to comply with all study requirements

Exclusion Criteria:

1. Prior exposure to a bromodomain inhibitor
2. Ongoing systemic infection requiring treatment with antibiotic, antiviral, or antifungal treatment
3. Autoimmune hemolytic anemia or autoimmune thrombocytopenia
4. Presence of symptomatic or uncontrolled central nervous system or leptomeningeal metastases
5. Red blood cell or platelet transfusion within 14 days of Screening blood draw
6. Known or suspected allergy to the investigational agent or any agent given in association with this study
7. Use of biotin (i.e., Vitamin B7) or supplements containing biotin higher than the daily adequate intake of 30 μg (NIH-ODS 2020).
8. Use of strong inhibitors and inducers of CYP3A4 and 2C8
9. Clinically significant cardiac disease
10. Inability to take oral medication or significant nausea and vomiting, malabsorption, or significant small bowel resection that, in the opinion of the Investigator, would preclude adequate absorption
11. Non-healing wound, ulcer, or bone fracture
12. Infection with HIV-1 or HIV-2. Exception: subjects with well-controlled HIV (e.g., CD4 \>350/mm3 and undetectable viral load) are eligible.
13. Current active liver disease from any cause, including hepatitis A (hepatitis A virus immunoglobulin M positive), hepatitis B (hepatitis B virus \[HBV\] surface antigen positive), or hepatitis C (hepatitis C virus \[HCV\] antibody positive, confirmed by HCV ribonucleic acid).
14. Active known second malignancy with the exception of any of the following:

    * Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer
    * Adequately treated Stage I cancer from which the subject is currently in remission and has been in remission for ≥2 years
    * Any other cancer from which the subject has been disease-free for ≥3 years
15. Major surgery or significant traumatic injury within 28 days prior to Cycle 1 Day 1
16. Hospitalization for subacute bowel obstruction within 28 days prior to Cycle 1 Day 1
17. Receipt of anti-cancer therapy prior to Cycle 1 Day 1:

    * Chemotherapy, radiation therapy, or small molecule anti-cancer therapy for the treatment of cancer within 14 days or 5 half-lives (whichever is shorter) of Cycle 1 Day 1
    * Immune therapy or other biologic therapy (e.g., monoclonal antibodies, antibody-drug conjugates) for the treatment of cancer within 21 days or 5 half-lives (whichever is shorter) of Cycle 1 Day 1 Subjects can receive a stable dose of bisphosphonates for bone metastases, before and during the study as long as these were started at least 28 days prior to treatment with study drug.
18. Subject is participating in any other therapeutic clinical study (observational or registry studies are allowed).
19. Subjects who are pregnant or breast-feeding
20. Presence of any other medical, psychological, familial, sociological, or geographic condition potentially hampering compliance with the study protocol or would interfere with the study endpoints or the subject's ability to participate.

Primary outcomes:
measure: Phase 2a (PLX2853 Monotherapy): Number of Participants With Overall Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
timeFrame: From 8 weeks of treatment for only PLX2853 (Cycle 3 Day 1; 28 days per cycle) until completion of long term follow-up, an average of 6 months.
measure: Phase 1b (PLX2853 + Carboplatin Combination): Establish the Number of Participants Reaching MTD/RP2D for the Combination of PLX2853 and Carboplatin
timeFrame: From time of first dose of PLX2853 and carboplatin until 30 days of end of treatment an average of 6 months.
measure: Phase 2a (PLX2853 + Carboplatin Combination): Number of Participants Reaching ORR as Measured by RECIST v1.1
timeFrame: From 8 weeks of treatment with PLX2853 and Carboplatin (Cycle 3 Day 1; 28 days per cycle) until completion of long term follow-up, an average of 6 months.
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: The University of Chicago Medical Center
state: Illinois
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
city: Oklahoma City
country: United States
facility: University of Oklahoma - Stephenson Cancer Center
state: Oklahoma
city: Nashville
country: United States
facility: Tennessee Oncology / Sarah Cannon
state: Tennessee
city: Charlottesville
country: United States
facility: University of Virginia Health Systems
state: Virginia
city: Fairfax
country: United States
facility: Virginia Cancer Specialists, PC
state: Virginia
city: Seattle
country: United States
facility: University of Washington / Seattle Cancer Care Alliance
state: Washington
city: Toronto
country: Canada
facility: Princess Margaret Cancer Centre
state: Ontario
Study officials:
References: